Literature DB >> 25511681

Novel therapeutic combination demonstrates more than additive effects in cutaneous T-cell lymphoma.

Brittany O'Neill Dulmage1, Sara K Story, Louis D Falo, Larisa J Geskin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25511681      PMCID： PMC4847954          DOI： 10.3109/10428194.2014.995649

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  15 in total

1.  Low-dose oral bexarotene in combination with low-dose interferon alfa in the treatment of cutaneous T-cell lymphoma: clinical synergism and possible immunologic mechanisms.

Authors:  Karen S McGinnis; Jacqueline M Junkins-Hopkins; Glen Crawford; Michael Shapiro; Alain H Rook; Carmela C Vittorio
Journal:  J Am Acad Dermatol       Date:  2004-03       Impact factor: 11.527

2.  The influence of chromatin structure on DNA damage induced by nitrogen mustard and cisplatin analogues.

Authors:  Anne M Galea; Vincent Murray
Journal:  Chem Biol Drug Des       Date:  2010-06       Impact factor: 2.817

Review 3.  Anticancer activities of histone deacetylase inhibitors.

Authors:  Jessica E Bolden; Melissa J Peart; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2006-09       Impact factor: 84.694

4.  Vorinostat combined with bexarotene for treatment of cutaneous T-cell lymphoma: in vitro and phase I clinical evidence supporting augmentation of retinoic acid receptor/retinoid X receptor activation by histone deacetylase inhibition.

Authors:  Reinhard Dummer; Marc Beyer; Kenneth Hymes; Mirjam T Epping; Rene Bernards; Matthias Steinhoff; Wolfram Sterry; Helmut Kerl; Karl Heath; Janet D Ahern; James S Hardwick; Jose Garcia-Vargas; Katrin Baumann; Syed Rizvi; Stanley R Frankel; Sean J Whittaker; Chalid Assaf
Journal:  Leuk Lymphoma       Date:  2012-02-13

5.  Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience.

Authors:  Youn H Kim; Gina Martinez; Anna Varghese; Richard T Hoppe
Journal:  Arch Dermatol       Date:  2003-02

6.  Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma.

Authors:  Sean J Whittaker; Marie-France Demierre; Ellen J Kim; Alain H Rook; Adam Lerner; Madeleine Duvic; Julia Scarisbrick; Sunil Reddy; Tadeusz Robak; Jürgen C Becker; Alexey Samtsov; William McCulloch; Youn H Kim
Journal:  J Clin Oncol       Date:  2010-08-09       Impact factor: 44.544

Review 7.  WHO-EORTC classification for cutaneous lymphomas.

Authors:  Rein Willemze; Elaine S Jaffe; Günter Burg; Lorenzo Cerroni; Emilio Berti; Steven H Swerdlow; Elisabeth Ralfkiaer; Sergio Chimenti; José L Diaz-Perez; Lyn M Duncan; Florent Grange; Nancy Lee Harris; Werner Kempf; Helmut Kerl; Michael Kurrer; Robert Knobler; Nicola Pimpinelli; Christian Sander; Marco Santucci; Wolfram Sterry; Maarten H Vermeer; Janine Wechsler; Sean Whittaker; Chris J L M Meijer
Journal:  Blood       Date:  2005-02-03       Impact factor: 22.113

8.  Cutaneous T-cell lymphoma treatment using bexarotene and PUVA: a case series.

Authors:  Fiza Singh; Mark G Lebwohl
Journal:  J Am Acad Dermatol       Date:  2004-10       Impact factor: 11.527

9.  Lysine acetylation targets protein complexes and co-regulates major cellular functions.

Authors:  Chunaram Choudhary; Chanchal Kumar; Florian Gnad; Michael L Nielsen; Michael Rehman; Tobias C Walther; Jesper V Olsen; Matthias Mann
Journal:  Science       Date:  2009-07-16       Impact factor: 47.728

10.  Mycosis fungoides: management with topical nitrogen mustard.

Authors:  R T Hoppe; E A Abel; D G Deneau; N M Price
Journal:  J Clin Oncol       Date:  1987-11       Impact factor: 44.544
View more
  1 in total

1.  Jak-STAT Inhibition Mediates Romidepsin and Mechlorethamine Synergism in Cutaneous T-Cell Lymphoma.

Authors:  Jose R Cortes; Christina C Patrone; Stuart Aidan Quinn; Yuhan Gu; Marta Sanchez-Martin; Adam Mackey; Anisha J Cooke; Bobby B Shih; Anouchka P Laurent; Megan H Trager; Adolfo A Ferrando; Larisa J Geskin; Teresa Palomero
Journal:  J Invest Dermatol       Date:  2021-06-03       Impact factor: 7.590
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.